J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Patent
ETM-775 metabolite of ecteinascidin 743
Rinehart Kenneth Lloyd,Morales Jose J,Joel M. Reid,Isabel Reymundo,Floriano Pablo,Garcia Gravalos Lola +5 more
TL;DR: In this paper, the purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished, and three compounds have been identified to date, namely ETM 305, ETM 775 and ETM 204.
Journal ArticleDOI
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.
Naoko Takebe,Geraldine O'Sullivan Coyne,S. Kummar,Jerry M. Collins,Joel M. Reid,Richard Piekarz,Nancy Moore,Lamin Juwara,Barry C. Johnson,Rachel Bishop,Frank I. Lin,Esther Mena,Peter L. Choyke,M. Liza Lindenberg,Larry Rubinstein,Cecilia Monge Bonilla,Matthew P. Goetz,Matthew M. Ames,Renee M. McGovern,Howard Streicher,Joseph M. Covey,James H. Doroshow,Alice P. Chen +22 more
TL;DR: In this paper, a 3+3 phase 1 dose escalation format over 8 dose levels (DLs) was used for the expansion phase and was higher than doses administered in any previous study; it yielded higher plasma Z-endoxifen concentrations.
Journal ArticleDOI
Skeletal and Uterotrophic Effects of Endoxifen in Female Rats.
Anne Gingery,Urszula T. Iwaniec,Malayannan Subramaniam,Russell T. Turner,Kevin S. Pitel,Renee M. McGovern,Joel M. Reid,Ronald J. Marler,James N. Ingle,Matthew P. Goetz,John R. Hawse +10 more
TL;DR: The results demonstrate that endoxifen elicits beneficial effects on bone in ovary‐intact rats and protects against bone loss following ovariectomy and that it elicits partial agonistic effects on the uterus and skeleton in ovariectomized animals.
Journal ArticleDOI
Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits.
Uttio Roy Chowdhury,Rachel A. Kudgus,Tommy A. Rinkoski,Bradley H. Holman,Cindy K. Bahler,Cheryl R. Hann,Joel M. Reid,Peter I. Dosa,Michael P. Fautsch +8 more
TL;DR: Results suggest that CKPL1 is converted to levcromakalim in the eye and likely to some extent in the systemic circulation.
Journal ArticleDOI
ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), and synovial sarcoma: A Children's Oncology Group study.
James I. Geller,Joseph G. Pressey,Malcolm A. Smith,Rachel A. Kudgus,Renee A. Schoon,Renee M. McGovern,Mariana M. Cajaiba,Joel M. Reid,David Hall,Donald A. Barkauskas,Jeffrey S. Dome,Elizabeth Fox,Brenda J. Weigel +12 more
TL;DR: A phase 2 trial assessing the efficacy and tolerability of LM administered at the adult recommended phase 2 dose (RP2D) was conducted in children with relapsed tumors, and results show effects in Wilms tumor, rhabdomyosarcoma, and neuroblastoma.